Bioxyne lifts FY26 EBITDA guidance significantly. The biotechnology company upgraded its full-year EBITDA forecast to AUD16.5-19 million following record first-half results, with revenue reaching AUD31.3 million, up 149 percent year-on-year. The company achieved adjusted EBITDA of AUD8.3 million and net profit after tax of AUD7.3 million in the half. Bioxyne doubled its GMP clean room capacity and tripled storage capacity while successfully producing its first Australian-made MDMA capsules. International expansion accelerated with entries into UK, Germany, and Latin American markets, generating AUD2.7 million in German revenue alone during the half. The company completed a dual listing on the Frankfurt Stock Exchange and is developing a UK manufacturing facility in Scotland with completion targeted for June 2026. With cash reserves of AUD7.
Post from MarketNews_en
Log in to interact with content.